Characterization of prostanoid receptors mediating inhibition of histamine release from anti‐IgE‐activated rat peritoneal mast cells
Open Access
- 1 February 2000
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 129 (3) , 589-597
- https://doi.org/10.1038/sj.bjp.0703072
Abstract
Prostanoid receptors mediating inhibition of anti‐IgE induced histamine release from rat peritoneal mast cells have been characterized pharmacologically. PGD2 and the specific DP receptor agonists BW 245C and ZK 118182 were the most potent inhibitors with half‐maximal concentrations of 0.26, 0.06 and 0.02 μM respectively. The maximum inhibition attainable was 60–65% with 10−5 M BW 245C and ZK 118182. Among several EP receptor agonists investigated, only PGE2 and the EP2/EP3 receptor agonist misoprostol induced significant inhibition (46.8±4.7% at 10−4 M and 18.7±6.8% at 10−5 M respectively). The IP receptor agonists cicaprost and iloprost were both less potent than the DP agonists in inhibiting histamine release (45.2±3.3% and 35.1±2.5% inhibition respectively at 10−5 M), whereas PGF2α and the TP receptor agonist U‐46619 were only marginally effective. The EP4/TP receptor antagonist AH 23848 failed to affect the inhibitory actions of PGD2 or PGE2 even at 10−5 M, whereas the DP/EP1/EP2 receptor antagonist AH 6809 slightly enhanced the effect of PGD2 at 10−6 M. At concentrations of 3×10−6 to 10−5 M, the putative DP receptor antagonist ZK 138357 dose‐dependently suppressed the inhibitory activities of the DP agonists, PGE2 and cicaprost. The antagonism of ZK 138357 against the DP receptor agonists appeared to be competitive with pA2 values of around six. In conclusion, these data support our earlier proposal that an inhibitory DP receptor is the predominant prostanoid receptor in rat peritoneal mast cell. The properties of this receptor in relation to putative DP receptor subtypes reported in the literature are discussed. British Journal of Pharmacology (2000) 129, 589–597; doi:10.1038/sj.bjp.0703072Keywords
This publication has 48 references indexed in Scilit:
- Functional characterization of the prostanoid DP receptor in human myometriumEuropean Journal of Pharmacology, 1995
- Identification of prostaglandin E receptor ‘EP2’ cloned from mastocytoma cells as EP4 subtypeFEBS Letters, 1995
- Pro-inflammatory and anti-inflammatory effects of the stable prostaglandin D2 analogue, ZK 118.182European Journal of Pharmacology, 1994
- Histamine release and calcium concentrations in rat mast cells are dependent on intracellular ATP: Effects of prostaglandin D2Prostaglandins, Leukotrienes & Essential Fatty Acids, 1994
- Prostacyclin (PGI) Receptor Binding and Cyclic AMP Synthesis Activities of PGI1 Analogues, SM-10906 and Its Methyl Ester, SM-10902, in Mastocytoma P-815 Cells.Biological & Pharmaceutical Bulletin, 1994
- SC-46275: A potent and highly selective agonist at the EP3 receptorProstaglandins, Leukotrienes & Essential Fatty Acids, 1993
- Two types of prostacyclin receptor coupling to stimulation of adenylate cyclase and phosphatidylinositol hydrolysis in a cultured mast cell line, BNu-2c13 cellsCellular Signalling, 1993
- Differential regulation of thrombin- or ATP-induced mobilization of intracellular Ca2+ by prostacyclin receptor in mouse mastocytoma cellsBiochemical and Biophysical Research Communications, 1991
- Prostaglandin D2 receptor of mastocytoma P-815 cells — possible regulation by phosphorylation and dephosphorylationBiochimica et Biophysica Acta (BBA) - Biomembranes, 1989
- 9-Deoxy-Δ9-prostaglandin D2, a prostaglandin D2 derivative with potent antineoplastic and weak smooth muscle-contracting activitiesBiochemical and Biophysical Research Communications, 1982